This website is intended for healthcare professionals only

Trending Topic

4 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Personalized and predictive dermatology recognizes that each patient is unique and aims to comprehensively address all aspects of an individual’s skin health. This approach tailors skin care treatments based on a combination of factors, including genetic and epigenetic profiles, skin type, microbiome composition and the exposome (an individual’s lifetime exposures).1 Scientists are exploring how ecological […]

EADV 2026 highlights with Dr Melinda Gooderham

Melinda Gooderham
5 mins
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
EADV 2026
Published Online: Oct 22nd 2026

Dr Melinda Gooderham shares her EADV 2026 highlights, including updates on JAKi , zasocitinib versus deucravacitinib, and ICONIC-TOTAL findings on icotrokinra in psoriasis.


Expert Insights EADV

Melinda Gooderham: APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitisFollowing the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, we were delighted to catch up with touchDERMATOLOGY Editorial Board member, Dr Melinda Gooderham (SKiN Centre for Dermatology, Peterborough, Ontario, Canada). Having already discussed the late-breaking results from the phase 2 APEX (NCT06395948) trial evaluating zumilokibart in moderate-to-severe atopic dermatitis,1 Dr Gooderham shared her wider congress highlights.

We discussed key updates from the much-anticipated session on JAK inhibitors, which she co-chaired. The session attracted interest from healthcare professionals across dermatology, reflecting the growing use and investigation of these therapies in conditions including atopic dermatitis, alopecia areata, psoriatic disease, vitiligo, and hidradenitis suppurativa.

We also explored key psoriasis data, focusing on the head-to-head trial comparing zasocitinib with deucravacitinib and 2-year findings from ICONIC-TOTAL investigating icotrokinra for psoriasis affecting high-impact sites.2-3


Q. What were your key highlights from the JAK inhibitor session at EADV 2026?

 

read more

Transcript:

The room was packed, which I think really speaks to the interest in this field and how the number of new agents and new indications is really growing in dermatology. This is a medication that you are going to be using every day for your patients with different diagnoses.

I started off the symposium by just talking about the mechanism of action, so people could understand the difference between a competitive inhibitor and an allosteric inhibitor, and how selectivity is relative for competitive inhibitors, just to understand the differences because we have multiple agents.

Bruno Duarte then followed by talking about where it’s going, new indications and combination therapy, and highlighted that in 2020, we had no JAK inhibitors approved in dermatology, and now we have nine. So we’ve really come a long way in the past six years with new indications, most recently vitiligo being approved, but also a number of new drugs in alopecia areata – so that was an eye-opening development in our field.

Turning to safety, Ignasi Figueras explained the ORAL Surveillance study and where the boxed warning comes in, based on the rheumatoid arthritis (RA) population. He then showed a lot of data about our patients living with alopecia areata, vitiligo and atopic dermatitis, and how they are a different patient population overall, and that we don’t have the same rates of adverse events (AEs). We don’t have that same signal in venous thromboembolism, major adverse cardiovascular events (MACE) or malignancy. So that is, I think, reassuring.

Seemal Desai talked about long-term JAK inhibitor use, reviewing data on using these medications long term and highlighting that, with vitiligo, there’s a very slow response in comparison to something like atopic dermatitis, where we have improvement in itch within hours to days. With vitiligo, it’s a much longer treatment course, and we just need to be patient with those results.

Also I’d like to add that from a safety perspective, the one thing that we do see in all of the different conditions treated with JAK inhibitors, is herpes zoster, and that’s a reminder to think about vaccination and have that discussion with your patient.


Q. Which findings or other sessions stood out to you at EADV 2026?

The whole oral revolution in psoriasis stood out to me. We have reached such high levels of skin clearance with current biologics, and I think the next wave is now these oral agents.

At the EADV 2026 Congress, we had late-breaking data from the LATITUDE Atlas trial comparing zasocitinib, a highly selective, once-daily oral tyrosine kinase 2 (TYK2) allosteric inhibitor, with the approved oral TYK2 inhibitor deucravacitinib in moderate-to-severe plaque psoriasis. This is the first time we have had a head-to-head comparison of two drugs with the same mechanism of action, so that was an exciting presentation for me.2

The study had a very high bar: a 100% improvement in the Psoriasis Area and Severity Index (PASI 100). What we saw was that, with zasocitinib, around one-third of patients achieved PASI 100 compared with about 13% with deucravacitinib. That is around two and a half times as many patients with clear skin at Week 16. PASI 90, indicating a 90% improvement, was achieved by two-thirds of patients with zasocitinib versus one-third with deucravacitinib.

What this showed was that, even though these two agents share the same target, with that higher affinity and higher selectivity, we are seeing greater responses with zasocitinib, but no difference in safety.

At the congress, late-breaking data were also presented on icotrokinra, specifically the 2-year data from ICONIC-TOTAL. This randomized controlled trial investigated the long-term durability and safety of icotrokinra in high-impact site psoriasis: the scalp, genitals, palms, and soles.

The 2-year results showed sustained responses across these high-impact sites. At Week 112, approximately three-quarters of patients achieved a scalp-specific Investigator’s Global Assessment (ss-IGA) score of 0 or 1, indicating absent or very mild disease. Approximately 90% achieved clear or almost clear genital skin based on the static Physician’s Global Assessment of Genitalia (sPGA-G), while approximately two-thirds achieved clear or almost clear skin on the hands and feet based on the hand/foot Physician’s Global Assessment (hf-PGA).

These were good results that continued to improve, with no new safety signals for this oral peptide targeting the interleukin-23 receptor.

Note: This transcript has been lightly edited to ensure clarity.

References:

  1. Silverberg JI, et al. Efficacy and safety of zumilokibart (APG777), a half-life-extended anti-IL-13 antibody, in moderate-to-severe atopic dermatitis: Primary results from the phase 2 APEX Part B dose-regimen-finding study. Presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 30–October 3, 2026; Vienna, Austria
  2. Stein Gold, et al. (2026). Zasocitinib, a highly selective, once-daily oral TYK2 inhibitor, demonstrates superior skin clearance (PASI 100) versus an approved oral TYK2 inhibitor, deucravacitinib, and a consistent safety profile in moderate-to-severe plaque psoriasis: Results from a randomized phase 3 intraclass head-to-head trial (LATITUDE Atlas). Presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 30–October 3, 2026; Vienna, Austria.
  3. Warren RB, et al. Long-term durability and safety of the targeted oral peptide icotrokinra for high-impact site psoriasis: 2-year findings from the ICONIC-TOTAL randomized controlled trial. Abstract LB-245. Presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 30–October 3, 2026; Vienna, Austria.

Cite: EADV 2026 highlights with Dr Melinda Gooderham. touchDERMATOLOGY. October 22, 2026.

Disclosure: No funding was received for the publication of this content. Thank you to Dr Gooderham for sharing her expert insights. Dr. Melinda Gooderham discloses: Advisory board/panel fees from AbbVie, Amgen, Apogee Therapeutics, Arcutis Biotherapeutics, Bausch Health, Boehringer Ingelheim, Eli Lilly and Company, Galderma SA, Janssen, LEO Pharma, L’Oréal, Novartis Pharmaceuticals, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, UCB, and UNION Therapeutics. Consultancy fees from AbbVie, Amgen, Apollo Therapeutics, Arcutis Biotherapeutics, Bausch Health, Boehringer Ingelheim, Eli Lilly and Company, Janssen, Novartis Pharmaceuticals, Organon Canada, Sanofi Genzyme, Sun Pharmaceuticals, and UCB. Grants/research support from AbbVie, ACELYRIN, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Aristea Therapeutics, Attovia Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Dermira, Eli Lilly and Company, Galderma SA, GSK, Incyte Biosciences, Insmed, Jamp Pharma, Janssen, LEO Pharma, Meiji Seika Pharma, Merck, MoonLake Immunotherapeutics, Nectar Therapeutics, Novartis Pharmaceuticals, Organon Canada, Oruka Therapeutics, Pfizer, Q32 Bio, Regeneron Pharmaceuticals, Reistone Biopharma, Sanofi Genzyme, Sun Pharmaceuticals, Takeda, Tarsus, UCB, Ventyx, and Vyne Therapeutics. Speaker’s bureau fees from AbbVie, Amgen, Arcutis Biotherapeutics, Bausch Health, Boehringer Ingelheim, Eli Lilly and Company, Galderma SA, GSK, Jamp Pharma, Janssen, LEO Pharma, L’Oréal, Novartis Pharmaceuticals, Organon Canada, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharmaceuticals, and UCB.

Editor: Gina Furnival, Head of Content

touchDERMATOLOGY coverage of EADV 2026: This content has been developed independently by Touch Medical Media for touchDERMATOLOGY. touchDERMATOLOGY was an official media partner of the EADV Congress 2026. touchDERMATOLOGY is not affiliated with the EADV. Views expressed are the speaker’s own and do not necessarily reflect the views of Touch Medical Media.

 

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Open Nav
touchConference Hub
Section 2 of 3 Part 7 of 9

touchDERMATOLOGY coverage of EADV Congress 2026

Prev Part
Next Part
touchConference Hub

touchDERMATOLOGY coverage of EADV Congress 2026

Late-breaking data

Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham
Further APEX data supports zumilokibart's potential as a less frequent dosing biologic option for atopic dermatitis; Melinda Gooderham

Further APEX data supports zumilokibart’s potential as a less frequent dosing option for atopic dermatitis

Part B of the phase 2 APEX trial evaluated three zumilokibart dosing regimens in adults with moderate-to-severe atopic dermatitis. All three met the primary endpoint at Week 16, with findings supporting mid dose selection for phase 3. Dr Melinda Gooderham discusses the efficacy and safety results from both Part A and Part B and what they could mean for clinical practice and those living with AD.
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter
Abdakibart in hidradenitis suppurativa: What we learned from LOTUS; Martina Porter

Abdakibart in hidradenitis suppurativa: What we learned from LOTUS

Could abdakibart offer a new treatment option for hidradenitis suppurativa? Dr Martina L. Porter discusses encouraging findings from the phase 2 LOTUS trial, including improvements in disease severity and draining tunnels, alongside a reassuring safety profile over 16 weeks, and considers what these results could mean for clinical practice.
Safety of dupilumab in pregnancy explored in final registry results
Safety of dupilumab in pregnancy explored in final registry results

Safety of dupilumab in pregnancy explored in final registry results

For women taking dupilumab to manage atopic dermatitis or asthma, limited pregnancy safety data can make treatment decisions challenging. Dr Christina Chambers discusses reassuring findings from a registry study of 539 pregnancies and how they could help clinicians counsel women who are pregnant or planning a family.

JAKPPPOT investigates the feasibility of a definitive JAKi trial in palmoplantar pustulosis

Encouraging findings from JAKPPPOT support the feasibility of a definitive randomized controlled trial of Janus kinase inhibitors in palmoplantar pustulosis and provide an exploratory estimate of treatment effect. We spoke with Dr David Gleeson about the results presented at EADV 2026 and their implications for future research.
0 mins

Topical RLS-1496 reduces actinic keratosis lesion counts

RLS-1496 1% cream is an investigational senotherapeutic treatment that inhibits GPX4. It aims to target senescent cells, potentially offering a new approach to treating actinic keratosis (AK). Encouraging findings from a phase 1b/2a, multicenter, open-label study were presented at EADV 2026. We spoke with Dr Mary Spellman, who presented the findings, about the results and their implications for the treatment’s future development.
Show All...
Currently viewing

Expert insights

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial
Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab shows potential in treating palmoplantar pustulosis in LEDA trial

Sonelokimab showed encouraging results in the phase 2 LEDA trial in adults with palmoplantar pustulosis. Dr Nina Magnolo discusses the findings, including a mean 64% reduction in disease severity at Week 16, and their potential implications for patients.
Mario Valenti, bimekizumab in hidradenitis suppurativa
Mario Valenti, bimekizumab in hidradenitis suppurativa

Real-world outcomes of bimekizumab in hidradenitis suppurativa

How does bimekizumab perform in everyday clinical practice? An Italian multicenter study reported improvements in disease activity, pain, and quality of life in people with hidradenitis suppurativa, with no unexpected safety signals. Dr Mario Valenti shares the findings and his perspective with touchDERMATOLOGY.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

Drug repurposing to advance treatment for rare genetic skin diseases

Drug repurposing could offer new treatment opportunities for rare genetic skin diseases. Prof. Dédée Murrell discusses the rationale for exploring existing medicines, progress in epidermolysis bullosa, and how a new trial aims to match treatments to patients’ inflammatory profiles rather than their genetic subtype.
Maria-Angeliki Gkini
Maria-Angeliki Gkini

EADV 2026: Psoriasis highlights and implications for clinical practice

On Day 2 of the EADV 2026 congress, we were delighted to speak with touchDERMATOLOGY Editorial Board member, Dr Maria Angeliki Gkini who shared her highlights from key psoriasis sessions and discussed what these developments could mean for clinical practice.
Prof. Dédée Murrell; The Women’s Dermatologic Society
Prof. Dédée Murrell; The Women’s Dermatologic Society

The Women’s Dermatologic Society at EADV 2026

What did the Women’s Dermatologic Society bring to EADV 2026? Explore session highlights spanning blistering diseases, skin cancer, scarring alopecias, and more. Prof. Dedee Murrell introduces the society’s focus on mentorship, explains why the session is worth watching, and shares why dermatologists should consider joining.

Could rezpegaldesleukin offer long-term remission in atopic dermatitis?

New 52-week REZOLVE-AD data showed durable responses with monthly and quarterly rezpegaldesleukin (REZPEG) maintenance dosing in atopic dermatitis. Prof. Thomas Bieber discusses the findings and the potential for long-term remission and disease modification, highlighting the further evidence needed to explore these goals.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.
Dr Melinda Gooderham reflects on her EADV 2026 highlights, including updates in JAKi, zasocitinib vs. deucravacitinib, and the ICONIC-TOTAL findings on icotrokinra in psoriasis.

EADV 2026 highlights with Dr Melinda Gooderham

What were the key dermatology updates at EADV 2026? Dr Melinda Gooderham shares her highlights, exploring the Janus kinase (JAK) inhibitors session, new data comparing zasocitinib with deucravacitinib, and 2-year findings from ICONIC-TOTAL evaluating icotrokinra.
Ashraf Badawi
Ashraf Badawi

Key updates in the field of laser and energy-based devices

From pruritus and burn scars to cutaneous neurofibromas, Prof. Ashraf Badawi explores some of the new directions for lasers and energy-based devices discussed at this years EADV congress.

Study links glucagon-like peptide-1 receptor agonist use with nail disorders

Could glucagon-like peptide-1 receptor agonists affect nail health? A multinational study presented at EADV 2026 found nail disorders were reported more frequently among users, with nearly sevenfold higher odds of nail detachment. Prof. Bianca Maria Piraccini discusses the findings and why further clinical assessment is needed.
Show All...

News

3 mins

touchDERMATOLOGY announces new media partnership with the EADV Congress

Through our new collaboration, we will work together to increase the visibility of important developments in dermatology, from the latest clinical research and scientific advances to key society news and updates. As part of the partnership, touchDERMATOLOGY will also bring our community independent coverage directly from the EADV Congress, including the latest data, expert perspectives, key clinical takeaways and onsite interviews with leading specialists.
3 mins

Your quick guide to keynote and plenary sessions at EADV 2026

With EADV Congress 2026 just around the corner, there is plenty to look forward to in Vienna from 30 September to 3 October. If you are joining this year, whether onsite or online, the keynote and plenary sessions are well worth making time for in your congress schedule.

Day 1: Late breakers, JAK inhibitors and keynote lecture open EADV 2026

The EADV Congress opens in Vienna on Wednesday, 30 September. Day 1 highlights include a midday plenary, two late-breaking sessions, a focus on JAK inhibitors, and a closing keynote on the COVID-19 pandemic and the infodemic.
Close Popup